User profiles for Maya Buch
 | Maya H BuchUniversity of Manchester Verified email at manchester.ac.uk Cited by 29265 |
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
…, M Boers, AA Den Broeder, MH Buch… - Annals of the …, 2020 - ard.bmj.com
Objectives To provide an update of the European League Against Rheumatism (EULAR)
rheumatoid arthritis (RA) management recommendations to account for the most recent …
rheumatoid arthritis (RA) management recommendations to account for the most recent …
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
…, R Landewé, FC Breedveld, M Buch… - Annals of the …, 2014 - ard.bmj.com
In this article, the 2010 European League against Rheumatism (EULAR) recommendations
for the management of rheumatoid arthritis (RA) with synthetic and biological disease-…
for the management of rheumatoid arthritis (RA) with synthetic and biological disease-…
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
Treatment of rheumatoid arthritis (RA) may differ among rheumatologists and currently, clear
and consensual international recommendations on RA treatment are not available. In this …
and consensual international recommendations on RA treatment are not available. In this …
Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA)
Background Patients with rheumatoid arthritis (RA) are at increased risk of developing
comorbid conditions. Objectives To evaluate the prevalence of comorbidities and compare their …
comorbid conditions. Objectives To evaluate the prevalence of comorbidities and compare their …
Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the …
Objectives To review the evidence for the efficacy and safety of biological agents in patients
with rheumatoid arthritis (RA) to provide data to develop treatment recommendations by the …
with rheumatoid arthritis (RA) to provide data to develop treatment recommendations by the …
Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis
MH Buch, JS Smolen, N Betteridge… - Annals of the …, 2011 - ard.bmj.com
Background Since initial approval for the treatment of rheumatoid arthritis (RA), rituximab has
been evaluated in clinical trials involving various populations with RA. Information has also …
been evaluated in clinical trials involving various populations with RA. Information has also …
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial
…, M Sharafat, R Stewart, B Rudran, JK Baillie, MH Buch… - Medrxiv, 2021 - medrxiv.org
Background Tocilizumab is a monoclonal antibody that binds to the receptor for interleukin (IL)-6,
reducing inflammation, and is commonly used to treat rheumatoid arthritis. We …
reducing inflammation, and is commonly used to treat rheumatoid arthritis. We …
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
…, T Bewick, S Tiberi, T Felton, JK Baillie, MH Buch… - Medrxiv, 2021 - medrxiv.org
Background REGEN-COV is a combination of 2 monoclonal antibodies (casirivimab and
imdevimab) that bind to two different sites on the receptor binding domain of the SARS-CoV-2 …
imdevimab) that bind to two different sites on the receptor binding domain of the SARS-CoV-2 …
EULAR definition of difficult-to-treat rheumatoid arthritis
…, KL Hyrich, U Mueller-Ladner, MH Buch… - Annals of the …, 2021 - ard.bmj.com
Background Despite treatment according to the current management recommendations, a
significant proportion of patients with rheumatoid arthritis (RA) remain symptomatic. These …
significant proportion of patients with rheumatoid arthritis (RA) remain symptomatic. These …
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
Objectives To provide an update of the EULAR rheumatoid arthritis (RA) management
recommendations addressing the most recent developments in the field. Methods An international …
recommendations addressing the most recent developments in the field. Methods An international …